Atinumab

DB17923InvestigationalProtein Based Therapies

ATI-355 is a humanized anti-Nogo-A antibody developed by Novartis.

Mechanism
Curator reviewed
Code names
ATI-355 · NG-101

Resolves to

Compound
UNII9UBQ62RW32
Targets
Q9NQC3RTN4

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
5Clinical trialsPhase, status and sponsor resolved per trial
Sign in
2+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Atinumab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In